Prognostic Impacts of D816V <i>KIT</i> Mutation and Peri-Transplant <i>RUNX1–RUNX1T1</i> MRD Monitoring on Acute Myeloid Leukemia with <i>RUNX1–RUNX1T1</i>
The prognostic significance of <i>KIT</i> mutations and optimal thresholds and time points of measurable residual disease (MRD) monitoring for acute myeloid leukemia (AML) with <i>RUNX1-RUNX1T1</i> remain controversial in the setting of hematopoietic stem cell transplantation...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/2/336 |
| _version_ | 1797410182422069248 |
|---|---|
| author | Byung-Sik Cho Gi-June Min Sung-Soo Park Silvia Park Young-Woo Jeon Seung-Hwan Shin Seung-Ah Yahng Jae-Ho Yoon Sung-Eun Lee Ki-Seong Eom Yoo-Jin Kim Seok Lee Chang-Ki Min Seok-Goo Cho Dong-Wook Kim Jong Wook-Lee Myung-Shin Kim Yong-Goo Kim Hee-Je Kim |
| author_facet | Byung-Sik Cho Gi-June Min Sung-Soo Park Silvia Park Young-Woo Jeon Seung-Hwan Shin Seung-Ah Yahng Jae-Ho Yoon Sung-Eun Lee Ki-Seong Eom Yoo-Jin Kim Seok Lee Chang-Ki Min Seok-Goo Cho Dong-Wook Kim Jong Wook-Lee Myung-Shin Kim Yong-Goo Kim Hee-Je Kim |
| author_sort | Byung-Sik Cho |
| collection | DOAJ |
| description | The prognostic significance of <i>KIT</i> mutations and optimal thresholds and time points of measurable residual disease (MRD) monitoring for acute myeloid leukemia (AML) with <i>RUNX1-RUNX1T1</i> remain controversial in the setting of hematopoietic stem cell transplantation (HSCT). We retrospectively evaluated 166 high-risk patients who underwent allogeneic (Allo-HSCT, <i>n</i> = 112) or autologous HSCT (Auto-HSCT, <i>n</i> = 54). D816V <i>KIT</i> mutation, a subtype of exon 17 mutations, was significantly associated with post-transplant relapse and poor survival, while other types of mutations in exons 17 and 8 were not associated with post-transplant relapse. Pre- and post-transplant <i>RUNX1–RUNX1T1</i> MRD assessments were useful for predicting post-transplant relapse and poor survival with a higher sensitivity at later time points. Survival analysis for each stratified group by D816V <i>KIT</i> mutation and pre-transplant <i>RUNX1–RUNX1T1</i> MRD status demonstrated that Auto-HSCT was superior to Allo-HSCT in MRD-negative patients without D816V <i>KIT</i> mutation, while Allo-HSCT was superior to Auto-HSCT in MRD-negative patients with D816V <i>KIT</i> mutation. Very poor outcomes of pre-transplant MRD-positive patients with D816V <i>KIT</i> mutation suggested that this group should be treated in clinical trials. Risk stratification by both D816V <i>KIT</i> mutation and <i>RUNX1–RUNX1T1</i> MRD status will provide a platform for decision-making or risk-adapted therapeutic approaches. |
| first_indexed | 2024-03-09T04:26:11Z |
| format | Article |
| id | doaj.art-cc9c15cebbb3438da1f52ec6e033d789 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T04:26:11Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-cc9c15cebbb3438da1f52ec6e033d7892023-12-03T13:40:25ZengMDPI AGCancers2072-66942021-01-0113233610.3390/cancers13020336Prognostic Impacts of D816V <i>KIT</i> Mutation and Peri-Transplant <i>RUNX1–RUNX1T1</i> MRD Monitoring on Acute Myeloid Leukemia with <i>RUNX1–RUNX1T1</i>Byung-Sik Cho0Gi-June Min1Sung-Soo Park2Silvia Park3Young-Woo Jeon4Seung-Hwan Shin5Seung-Ah Yahng6Jae-Ho Yoon7Sung-Eun Lee8Ki-Seong Eom9Yoo-Jin Kim10Seok Lee11Chang-Ki Min12Seok-Goo Cho13Dong-Wook Kim14Jong Wook-Lee15Myung-Shin Kim16Yong-Goo Kim17Hee-Je Kim18Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaThe prognostic significance of <i>KIT</i> mutations and optimal thresholds and time points of measurable residual disease (MRD) monitoring for acute myeloid leukemia (AML) with <i>RUNX1-RUNX1T1</i> remain controversial in the setting of hematopoietic stem cell transplantation (HSCT). We retrospectively evaluated 166 high-risk patients who underwent allogeneic (Allo-HSCT, <i>n</i> = 112) or autologous HSCT (Auto-HSCT, <i>n</i> = 54). D816V <i>KIT</i> mutation, a subtype of exon 17 mutations, was significantly associated with post-transplant relapse and poor survival, while other types of mutations in exons 17 and 8 were not associated with post-transplant relapse. Pre- and post-transplant <i>RUNX1–RUNX1T1</i> MRD assessments were useful for predicting post-transplant relapse and poor survival with a higher sensitivity at later time points. Survival analysis for each stratified group by D816V <i>KIT</i> mutation and pre-transplant <i>RUNX1–RUNX1T1</i> MRD status demonstrated that Auto-HSCT was superior to Allo-HSCT in MRD-negative patients without D816V <i>KIT</i> mutation, while Allo-HSCT was superior to Auto-HSCT in MRD-negative patients with D816V <i>KIT</i> mutation. Very poor outcomes of pre-transplant MRD-positive patients with D816V <i>KIT</i> mutation suggested that this group should be treated in clinical trials. Risk stratification by both D816V <i>KIT</i> mutation and <i>RUNX1–RUNX1T1</i> MRD status will provide a platform for decision-making or risk-adapted therapeutic approaches.https://www.mdpi.com/2072-6694/13/2/336AML<i>RUNX1–RUNX1T1</i>D816V <i>KIT</i> mutationhematopoietic stem cell transplantationmeasurable residual disease |
| spellingShingle | Byung-Sik Cho Gi-June Min Sung-Soo Park Silvia Park Young-Woo Jeon Seung-Hwan Shin Seung-Ah Yahng Jae-Ho Yoon Sung-Eun Lee Ki-Seong Eom Yoo-Jin Kim Seok Lee Chang-Ki Min Seok-Goo Cho Dong-Wook Kim Jong Wook-Lee Myung-Shin Kim Yong-Goo Kim Hee-Je Kim Prognostic Impacts of D816V <i>KIT</i> Mutation and Peri-Transplant <i>RUNX1–RUNX1T1</i> MRD Monitoring on Acute Myeloid Leukemia with <i>RUNX1–RUNX1T1</i> Cancers AML <i>RUNX1–RUNX1T1</i> D816V <i>KIT</i> mutation hematopoietic stem cell transplantation measurable residual disease |
| title | Prognostic Impacts of D816V <i>KIT</i> Mutation and Peri-Transplant <i>RUNX1–RUNX1T1</i> MRD Monitoring on Acute Myeloid Leukemia with <i>RUNX1–RUNX1T1</i> |
| title_full | Prognostic Impacts of D816V <i>KIT</i> Mutation and Peri-Transplant <i>RUNX1–RUNX1T1</i> MRD Monitoring on Acute Myeloid Leukemia with <i>RUNX1–RUNX1T1</i> |
| title_fullStr | Prognostic Impacts of D816V <i>KIT</i> Mutation and Peri-Transplant <i>RUNX1–RUNX1T1</i> MRD Monitoring on Acute Myeloid Leukemia with <i>RUNX1–RUNX1T1</i> |
| title_full_unstemmed | Prognostic Impacts of D816V <i>KIT</i> Mutation and Peri-Transplant <i>RUNX1–RUNX1T1</i> MRD Monitoring on Acute Myeloid Leukemia with <i>RUNX1–RUNX1T1</i> |
| title_short | Prognostic Impacts of D816V <i>KIT</i> Mutation and Peri-Transplant <i>RUNX1–RUNX1T1</i> MRD Monitoring on Acute Myeloid Leukemia with <i>RUNX1–RUNX1T1</i> |
| title_sort | prognostic impacts of d816v i kit i mutation and peri transplant i runx1 runx1t1 i mrd monitoring on acute myeloid leukemia with i runx1 runx1t1 i |
| topic | AML <i>RUNX1–RUNX1T1</i> D816V <i>KIT</i> mutation hematopoietic stem cell transplantation measurable residual disease |
| url | https://www.mdpi.com/2072-6694/13/2/336 |
| work_keys_str_mv | AT byungsikcho prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT gijunemin prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT sungsoopark prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT silviapark prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT youngwoojeon prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT seunghwanshin prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT seungahyahng prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT jaehoyoon prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT sungeunlee prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT kiseongeom prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT yoojinkim prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT seoklee prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT changkimin prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT seokgoocho prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT dongwookkim prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT jongwooklee prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT myungshinkim prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT yonggookim prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i AT heejekim prognosticimpactsofd816vikitimutationandperitransplantirunx1runx1t1imrdmonitoringonacutemyeloidleukemiawithirunx1runx1t1i |